Literature DB >> 21093703

[Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis].

E Arroyo1, M González, C Grau, C Arnal, M Bujanda, P de Castro, L Grau, M Martínez, C Ramo, V Sánchez, O Sánchez-Soliño.   

Abstract

INTRODUCTION: The objective of this work was to assess the factors identified in the Global Adherence Project (GAP) in disease-modifying therapy (DMT) in patients with multiple sclerosis (MS) and to propose measures directed at improving adherence. It was proposed to prepare questionnaires to detect patients at risk of non-adherence before and during the follow-up.
METHODS: Two meetings were held by Spanish researchers involved in the GAP project. Factors associated with non-adherence were grouped in therapy-, patient-, disease- and health care professional-related factors. Four working groups were created. Each group studied one individual,factor, taking into account the stages of diagnosis, management and administering treatment, follow-up and discontinuation or change of treatment. A draft of proposals and tools (questionnaires) was agreed.
RESULTS: Patients should be provided with summaries of treatments, in a positive and simple way, and have time to discuss any doubts. Questionnaires should be given to patients at the start of treatment and during follow-up, so that individual characteristics can be assessed in order to monitor their adherence and act accordingly. Patients should be instructed in the management of the most common adverse reactions.
CONCLUSION: Therapeutic education to improve adherence to treatments and identification of non-adherent patients is recommended. We propose 2 questionnaires, initial and follow up, to stratify patients depending on their adherence.
Copyright © 2009 Sociedad Española de Neurología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21093703     DOI: 10.1016/j.nrl.2010.07.004

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  1 in total

1.  BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®.

Authors:  Francesco Patti; María Luisa Martínez Ginés; Christiane Norenberg; Fernando Duarte Caron
Journal:  Patient Prefer Adherence       Date:  2020-04-28       Impact factor: 2.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.